2000-Year of the Biotechs! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2000-Year of the Biotechs!

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Volcano888 who wrote (1111)	11/17/2000 2:33:40 AM
From: Toni Wheeler	Read Replies (1) of 1142

Volcano....exactly my points and your questions were much better at telling the "story" than my 'dissertation'! ~gg~ We are on the same wavelength, nonetheless. It appears GNLB has run out ahead with their solutions....the FDA should be weighing in soon with answers [fast-track and orphan drug status aiding the decision]. We've been told Watson finds Aslera compelling.... Monday November 13, 6:01 am Eastern Time Press Release SOURCE: Watson Pharmaceuticals, Inc. Watson Pharmaceuticals and Genelabs Technologies Enter Into Collaboration and License Agreement for Lupus Drug "Watson Also to Purchase Shares of Genelabs Common Stock...." biz.yahoo.com also see more at genelabs.com btw....might I add to your excellent questions? What additional 'drug research/technologies' from GNLB could have been intriguing to Watson Pharm?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next